Combination Therapy for Multiple SclerosisThe Treatment Strategy of the Future?
作者:
Bianca Weinstock-Guttman,
Rohit Bakshi,
期刊:
CNS Drugs
(ADIS Available online 2004)
卷期:
Volume 18,
issue 12
页码: 777-792
ISSN:1172-7047
年代: 2004
出版商: ADIS
关键词: Glatiramer acetate, therapeutic use;Azathioprine, therapeutic use;Methotrexate, therapeutic use;Immunoglobulins, therapeutic use;Interferon beta 1a, therapeutic use;Interferon beta 1b, therapeutic use;Mitoxantrone, therapeutic use;Immunomodulators, therap
数据来源: ADIS
摘要:
Multiple sclerosis (MS) is an inflammatory autoimmune disease characterised by demyelination and axonal loss in the CNS. Although new immunomodulatory therapies including interferon-β and glatiramer acetate became available during the last decade, these therapies are only partially effective. There is a continuing need to develop more effective treatment strategies to combat the chronic and progressive aspects of the disease. In view of the complex pathophysiology underlying the MS disease process, combination therapy offers a rational therapeutic approach. Combining immunomodulatory agents with different mechanisms of action that promote synergistic or additive effects represents an important objective in MS therapeutic research. Ultimately, the optimal therapies will likely include strategies that promote repair and limit tissue destruction in combination with anti-inflammatory interventions.
点击下载:
PDF
(285KB)
返 回